Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ebphCfbwoceUAHnhohcf

December 5, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • FDA appears ready to rethink antibiotic development
    An advisory panel's vote last week is among the signals that the FDA may be ready to reconsider the requirements for the clinical trials of antibiotics. As multidrug-resistant bacteria strains have become more common, new antibiotic approvals have decreased. Nature (12/4) LinkedInFacebookTwitterEmail this Story
New Discoveries in Parkinson's Point to Biomarkers, Therapies
Although Parkinson's disease (PD) is estimated to be the second most common neurodegenerative disorder, very little is known about its underlying cause. That could be about to change as scientists continue to drill down in the molecular machinery implicated in the disease. Find out the details.

  Health Care & Policy 
  • AVEO, Astellas kick off Phase II trial of cancer drug tivozanib
    Enrollment has started for AVEO Oncology and Astellas Pharma's trial of the experimental cancer drug tivozanib, which is currently under review by the FDA for advanced renal cell carcinoma. The multicenter trial will evaluate the safety and efficacy of tivozanib plus paclitaxel in comparison with placebo and paclitaxel in the treatment of locally recurrent or metastatic triple negative breast cancer in patients who have yet to receive systemic therapy. Pharmaceutical Business Review Online (12/4) LinkedInFacebookTwitterEmail this Story
  • Merck begins midstage study of Alzheimer's treatment
    Merck & Co. has kicked off a Phase II trial of MK-8931, an oral drug to block the production of beta amyloid proteins that develop into brain plaque in patients with Alzheimer's disease. The multicenter trial, which involves 200 patients with mild to moderate disease symptoms, will compare the treatment with a placebo. Reuters (12/3) LinkedInFacebookTwitterEmail this Story
  • Cell transplant improves function in monkeys with Parkinson's
    Transplants of bone marrow stem cells safely improved motor skills in macaque monkeys with Parkinson's disease, according to a Japanese study published in the Journal of Clinical Investigation. In the study, the cells were derived from the monkeys' own bone marrow, so there was no risk of tissue rejection. The researchers said the method "may expand the availability of cell sources for cell-based therapies for patients with Parkinson's disease." Los Angeles Times/Science Now blog (tiered subscription model) (12/3) LinkedInFacebookTwitterEmail this Story
 
  Company & Financial News 
  Food & Agriculture 
  Industrial & Environmental 
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The forceps of our minds are clumsy things and crush the truth a little in the course of taking hold of it."
--H.G. Wells,
British author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information